Prime Drink Group Announces Subscription Receipt Financing and Closing of Second Tranche of Private Placement of UnitsBusiness Wire · Oct 15, 2026
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's WhyZacks Investment Research · Oct 12, 2026
Leading Indicators For The October Breakout CycleSeeking Alpha · Oct 11, 2026
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson DiseaseGlobeNewsWire · Oct 5, 2026
Prime Medicine Gets FDA Green Light for Gene Editing StudyBenzinga · Sep 25, 2026
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin DeficiencyGlobeNewsWire · Sep 24, 2026Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.26 | -$0.24 | Beat |
| May 7, 2026 | -$0.24 | -$0.28 | Miss |
| Mar 3, 2026 | -$0.25 | -$0.22 | Beat |
| Nov 7, 2025 | -$0.28 | -$0.32 | Miss |
| Aug 7, 2025 | -$0.36 | -$0.41 | Miss |
| May 8, 2025 | -$0.32 | -$0.40 | Miss |